TY - JOUR
T1 - Epithelial Paradox
T2 - Clinical Significance of Coexpression of E-cadherin and Vimentin With Regard to Invasion and Metastasis of Breast Cancer
AU - Yamashita, Nami
AU - Tokunaga, Eriko
AU - Iimori, Makoto
AU - Inoue, Yuka
AU - Tanaka, Kimihiro
AU - Kitao, Hiroyuki
AU - Saeki, Hiroshi
AU - Oki, Eiji
AU - Maehara, Yoshihiko
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/10
Y1 - 2018/10
N2 - E-cadherin and vimentin are regarded as major conventional canonical markers of epithelial–mesenchymal transition. Both E-cadherin– and vimentin-positive tumors had the worst prognosis among all cases. Further, E-cadherin and vimentin protein is colocalized within the same tumor cells, suggesting the existence of an aggressive subpopulation in the primary tumor nest of breast cancer. Background: E-cadherin and vimentin are regarded as major conventional canonical markers of the epithelial–mesenchymal transition. It is commonly assumed that E-cadherin is uniformly lost during the process of epithelial–mesenchymal transition. Breast tumor cells typically invade as a cohesive multicellular unit in a process called collective invasion. The aim of this study was to reveal the clinical importance of the expression pattern of E-cadherin and vimentin in breast cancer. Methods: E-cadherin and vimentin protein expression was evaluated by immunohistochemistry in 176 invasive breast cancer samples. Among these, E-cadherin and vimentin expression were evaluated in the set of primary site and metastatic lymph nodes in 65 cases. In addition, E-cadherin and vimentin expression were analyzed by confocal laser scanning microscopy to see E-cadherin and vimentin localization in the breast cancer cells. Results: Both at the primary site and metastatic lymph nodes, both E-cadherin– and vimentin-positive tumors had the worst disease-free and overall survival among all cases. In addition, E-cadherin and vimentin protein is colocalized within the same tumor cells in a human breast cancer specimen. Conclusion: Our present data suggest the existence of an aggressive subpopulation in the primary tumor nest of breast cancer.
AB - E-cadherin and vimentin are regarded as major conventional canonical markers of epithelial–mesenchymal transition. Both E-cadherin– and vimentin-positive tumors had the worst prognosis among all cases. Further, E-cadherin and vimentin protein is colocalized within the same tumor cells, suggesting the existence of an aggressive subpopulation in the primary tumor nest of breast cancer. Background: E-cadherin and vimentin are regarded as major conventional canonical markers of the epithelial–mesenchymal transition. It is commonly assumed that E-cadherin is uniformly lost during the process of epithelial–mesenchymal transition. Breast tumor cells typically invade as a cohesive multicellular unit in a process called collective invasion. The aim of this study was to reveal the clinical importance of the expression pattern of E-cadherin and vimentin in breast cancer. Methods: E-cadherin and vimentin protein expression was evaluated by immunohistochemistry in 176 invasive breast cancer samples. Among these, E-cadherin and vimentin expression were evaluated in the set of primary site and metastatic lymph nodes in 65 cases. In addition, E-cadherin and vimentin expression were analyzed by confocal laser scanning microscopy to see E-cadherin and vimentin localization in the breast cancer cells. Results: Both at the primary site and metastatic lymph nodes, both E-cadherin– and vimentin-positive tumors had the worst disease-free and overall survival among all cases. In addition, E-cadherin and vimentin protein is colocalized within the same tumor cells in a human breast cancer specimen. Conclusion: Our present data suggest the existence of an aggressive subpopulation in the primary tumor nest of breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85043273648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043273648&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2018.02.002
DO - 10.1016/j.clbc.2018.02.002
M3 - Article
C2 - 29526677
AN - SCOPUS:85043273648
SN - 1526-8209
VL - 18
SP - e1003-e1009
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 5
ER -